<DOC>
	<DOCNO>NCT00909389</DOCNO>
	<brief_summary>This study aim establish safety , tolerability , efficacy Vytorin ( R ) ( Ezetimibe + Simvastatin ) ( SCH 465981 ) select population Filipinos hypercholesterolemia .</brief_summary>
	<brief_title>Post-marketing Surveillance Safety , Tolerability Efficacy Vytorin ( Ezetimibe + Simvastatin ) Tablet Among Filipino Patients ( Study P05647 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>Outpatient men woman , age 18 year Patients primary ( heterozygous familial nonfamilial ) hypercholesterolemia Known hypersensitivity Ezetimibe Simvastatin Moderate severe hepatic insufficiency Persistent elevation serum transaminase level 1.5 time upper limit normal Pregnancy lactation Concomitant intake bile acid sequestrants ( resin ) , nicotinic acid ( niacin ) , fibric acid ( fibrates ) , cyclosporine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>